Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib?

Authors

  • Romain Coriat M.D., M.Sc.,

    1. Gastroenterology and Endoscopy Unit, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    2. Center for Research on Angiogenesis Inhibitors (CERIA), Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    Search for more papers by this author
  • Olivier Mir M.D., M.Sc.,

    1. Center for Research on Angiogenesis Inhibitors (CERIA), Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    Search for more papers by this author
  • François Goldwasser M.D., Ph.D.,

    1. Center for Research on Angiogenesis Inhibitors (CERIA), Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    Search for more papers by this author
  • Stanislas Pol M.D., Ph.D.,

    1. Liver Unit and Institut National de la Santé et de la Recherche Médicale (Inserm) U-1016, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    Search for more papers by this author
  • Stanislas Chaussade M.D., Ph.D.

    1. Gastroenterology and Endoscopy Unit, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Assistance Publique–Hopitaux de Paris, Paris, France
    Search for more papers by this author

  • Potential conflict of interest: Prof. Goldwasser has acted as paid consultant for Bayer. The other authors have no conflict of interest to declare.

No abstract is available for this article.

Ancillary